UNSPSC 51342402: Saquinavir

This classification denotes a protease inhibitor with the molecular formula C38H50N6O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L3JE09KZ2F, chemically known as butanediamide, n1-(3-(3-(((1,1-dimethylethyl)amino)carbonyl)octahydro-2(1h)-isoquinolinyl)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (3s-(2(1r*(r*),2s*),3alpha,4aalpha,8aalpha))- but generally known as saquinavir, which bears US NIH Compound Identifier 60787.

UNSPSC 51342402 Saquinavir is a Commodity code nominally tied to a specific antiretroviral drug, but recent state and local solicitations show little activity aligned with the code's scope. The most recent opportunities posted under this code involve naloxone procurement, direct-to-manufacturer pharmacy programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products — none of which directly relate to saquinavir or antiretroviral therapy. State and local health authorities, counties, and cooperative purchasing alliances are the issuing bodies driving activity in the pharmaceutical and medical supply space overall, but the mismatch between the code's nominal product and the work actually being solicited suggests this code sees limited relevant procurement volume or inaccurate code assignment in current opportunities.

Recent opportunities across the broader pharmaceutical and medical supply domain span Florida, Texas, and Minnesota through multi-state cooperative purchasing mechanisms. The Seminole County, Florida procurement (IFB 60459723LAS, due July 26, 2023) sought naloxone and drug deactivation systems on an annual basis; the Texas Health and Human Services Commission issued a Request for Information on direct-to-manufacturer prescription programs (HHS0017013, April 2026); the City of Tampa solicited medical and first aid supplies for its Fire Department Rescue Division (IFB 26P00145, March 2026, estimated at $700,000) with a Small Local Business Enterprise set-aside and 5 percent bid discount; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP for generic multi-source pharmaceuticals and OTC products (S1070000015802, due March 26, 2026) serving Minnesota, Oregon, and other participating jurisdictions. The code shows no specific recent solicitation activity for saquinavir or comparable antiretroviral drugs.